EyePoint Pharmaceuticals to host conference call on November 5, 2025, to discuss Q3 financial results and corporate developments.
Quiver AI Summary
EyePoint Pharmaceuticals, Inc. has announced a conference call and live webcast scheduled for November 5, 2025, at 8:30 a.m. ET to discuss its third quarter financial results and recent corporate updates. The event can be accessed via a registration link for the conference call and through the company's website. EyePoint focuses on developing innovative therapeutics for retinal diseases, with its lead candidate, DURAVYU™, a sustained delivery treatment for serious conditions like wet age-related macular degeneration (AMD). DURAVYU is currently undergoing Phase 3 trials, with data expected in mid-2026, and marks a significant advancement for EyePoint as the company aims to enhance patient outcomes while maintaining a strong presence in the retina therapeutic space.
Potential Positives
- EyePoint Pharmaceuticals will report third quarter 2025 financial results, providing transparency and updates on its financial health and corporate developments to investors.
- The company's lead product candidate, DURAVYU™, is advancing through crucial Phase 3 pivotal trials, indicating progress in the development of innovative treatments for serious retinal diseases.
- DURAVYU™ has received conditional acceptance of its proprietary name from the FDA, which is a significant step in the regulatory process for a new therapeutic product.
- EyePoint has a long history of creating value, with four approved drugs and significant clinical experience, underscoring its commitment to the retina community and patient care.
Potential Negatives
- The announcement of the conference call does not include any specific financial metrics or performance indicators from the third quarter, which may lead to speculation and concern about the company's financial health.
- There is uncertainty regarding the timeline for FDA approval and marketing authorization for DURAVYU™, which may affect investor confidence.
- The company only has one lead product candidate currently under evaluation, indicating a reliance on a single investigational product for future growth.
FAQ
When will EyePoint Pharmaceuticals announce its Q3 2025 results?
EyePoint Pharmaceuticals will announce its Q3 2025 results on November 5, 2025, at 8:30 a.m. ET.
How can I access EyePoint's conference call and webcast?
You can access the conference call by registering at the provided audio conference link and the webcast via the company’s website.
What is DURAVYU™ and its significance?
DURAVYU™ is an investigational sustained delivery treatment for serious retinal diseases, currently in Phase 3 trials for wet AMD and DME.
What is the status of EyePoint's clinical trials?
EyePoint's DURAVYU™ is in Phase 3 trials for wet AMD, with data expected in mid-2026; DME dosing starts in Q1 2026.
Is DURAVYU™ approved for sale?
No, DURAVYU™ is investigational and not authorized for sale in any country as of now.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- KAREN L. ZADEREJ has made 4 purchases buying 20,000 shares for an estimated $113,450 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EYPT Hedge Fund Activity
We have seen 73 institutional investors add shares of $EYPT stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 3,181,818 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $29,940,907
- PERCEPTIVE ADVISORS LLC removed 1,537,274 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $14,465,748
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,270,305 shares (-93.8%) from their portfolio in Q2 2025, for an estimated $11,953,570
- FINEPOINT CAPITAL LP removed 1,081,954 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,181,187
- ABERDEEN GROUP PLC added 800,456 shares (+346.9%) to their portfolio in Q2 2025, for an estimated $7,532,290
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 600,000 shares (+9.7%) to their portfolio in Q2 2025, for an estimated $5,646,000
- FEDERATED HERMES, INC. added 513,870 shares (+12.6%) to their portfolio in Q2 2025, for an estimated $4,835,516
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EYPT Analyst Ratings
Wall Street analysts have issued reports on $EYPT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/07/2025
- RBC Capital issued a "Outperform" rating on 06/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/29/2025
- Mizuho issued a "Outperform" rating on 05/16/2025
To track analyst ratings and price targets for $EYPT, check out Quiver Quantitative's $EYPT forecast page.
$EYPT Price Targets
Multiple analysts have issued price targets for $EYPT recently. We have seen 4 analysts offer price targets for $EYPT in the last 6 months, with a median target of $26.5.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $27.0 on 08/07/2025
- Yi Chen from HC Wainwright & Co. set a target price of $23.0 on 08/06/2025
- Lisa Walter from RBC Capital set a target price of $28.0 on 06/17/2025
- Graig Suvannavejh from Mizuho set a target price of $26.0 on 05/16/2025
Full Release
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments.
To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg . A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com . A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU ™ , is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E ™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901 (vorolanib intravitreal insert). DURAVYU is an investigational medicinal product and is not authorized for sale in any country at the present time. FDA approval in the United States and marketing authorization in any other country and the timeline for potential approval or authorization is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
[email protected]
/
[email protected]
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]
